A Phase 1 Study of JNJ-70218902, a T Cell Redirecting Agent, in Advanced Stage Solid Tumors
70218902EDI1001
Phase 1 other active
Quick answer
A Phase 1 Study of JNJ-70218902, a T Cell Redirecting Agent, in Advanced Stage Solid Tumors for Metastatic Castration-Resistant Prostate Cancer is a Phase 1 program (other) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Janssen-Cilag International N.V.
- Indication
- Metastatic Castration-Resistant Prostate Cancer
- Phase
- Phase 1
- Modality
- other
- Status
- active